Contact
searchSearch
HMP Global
Login
Quiz

Zanzalintinib Plus Atezolizumab in Relapsed/Refractory Metastatic Colorectal Cancer

Edited by 
Emily Estrada
04/01/2026
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.

Related Content

News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
Glecirasib-Based Regimens Show Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the...
05/07/2026
Oncology
News
ctDNA Dynamics to Predict Survival Outcomes in Patients With Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from...
05/07/2026
Oncology
Videos
Tumor Microenvironment Challenges in Refractory Metastatic Colorectal Cancer (mCRC): An Expert Debate
04/23/2026
Aparna Parikh, MD; Nataliya Uboha, MD, PhD; Kanwal Pratap Singh Raghav, MD
The management of refractory metastatic colorectal cancer (mCRC) remains constrained by a biologically resistant, immune-excluded tumor microenvironment. In this peer-led debate, experts examine how tumor...
The management of refractory metastatic colorectal cancer (mCRC) remains constrained by a biologically resistant, immune-excluded tumor microenvironment. In this peer-led debate, experts examine how tumor...
The management...
04/23/2026
Oncology

Recent News

News
Pembrolizumab Plus BCG Shows Bladder-Preserving Potential in Non-Muscle Invasive Bladder Cancer
05/20/2026
Stephanie Holland
Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.
Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.
Results from a phase 2 trial...
05/20/2026
Oncology
News
Aglatimagene Improves Disease-Free Survival in Patients With Localized Prostate Cancer
05/20/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial...
05/20/2026
Oncology
News
Tiragolumab Plus Atezolizumab and Chemotherapy in Extensive-Stage Small Cell Lung Cancer
05/19/2026
Emily Estrada
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3...
05/19/2026
Oncology
News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
Durvalumab Plus BCG Delays High-Risk Recurrence in Non-Muscle-Invasive Bladder Cancer
05/19/2026
Stephanie Holland
Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.
Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.
Updated results from the POTOMAC...
05/19/2026
Oncology
FDA Approval
FDA Approves Neoadjuvant and Adjuvant T-DXd for Patients With HER2-Positive Early Breast Cancer
05/18/2026
Stephanie Holland
Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.
Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.
Based on results from the phase...
05/18/2026
Oncology
FDA Approval
FDA Approves Atezolizumab for Patients with ctDNA-Positive Muscle-Invasive Bladder Cancer
05/15/2026
Emily Estrada
Based on results from the IMvigor011 trial, the FDA has approved adjuvant atezolizumab and atezolizumab plus hyaluronidase for ctDNA-positive patients with muscle-invasive bladder cancer.
Based on results from the IMvigor011 trial, the FDA has approved adjuvant atezolizumab and atezolizumab plus hyaluronidase for ctDNA-positive patients with muscle-invasive bladder cancer.
Based on results from the...
05/15/2026
Oncology
News
BTX-9341 Shows Promising Efficacy, Safety in HR-Positive, HER2-Negative Advanced Breast Cancer
05/15/2026
Emily Estrada
Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Results from the phase 1...
05/15/2026
Oncology
News
pCR Guided Chemotherapy De-Escalation Shows Promise in HER2-Positive Early Breast Cancer
05/15/2026
Emily Estrada
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided...
05/15/2026
Oncology
News
Zongertinib Demonstrates Clinical Promise in HER2-Mutated Non-Small Cell Lung Cancer
05/14/2026
Stephanie Holland
First-line treatment with zongertinib showed sustained efficacy in advanced or metastatic HER2-mutated non-small-cell lung cancer, according to results from the phase 1a/1b Beamion LUNG-1 trial.
First-line treatment with zongertinib showed sustained efficacy in advanced or metastatic HER2-mutated non-small-cell lung cancer, according to results from the phase 1a/1b Beamion LUNG-1 trial.
First-line treatment with...
05/14/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use